PEPTIDE_CODEX

← All peptides

PC-026 · nootropic · dihexa

Dihexa

N-hexanoic-Tyr-Ile-(6) aminohexanoic amide

animal studyin vitro

An oligopeptide derived from angiotensin IV that is reportedly 10 million times more potent than BDNF at promoting new neural connections. Dihexa was developed at Washington State University and has shown remarkable cognitive enhancement in animal studies, particularly for memory restoration.

Binds to hepatocyte growth factor (HGF) and its receptor c-Met, dramatically amplifying HGF/c-Met signaling in the brain. This promotes dendritic spine formation, synaptic connectivity, and neuronal repair. The mechanism is distinct from traditional nootropics.

  • Cognitive enhancement
  • Memory improvement
  • Neural repair
  • Alzheimer's research
  • · Unknown (no human trials)
  • · Theoretical cancer risk (HGF/c-Met pathway)
  • · Headache (anecdotal)

Mechanism of Action

Binds to hepatocyte growth factor (HGF) and its receptor c-Met, dramatically amplifying HGF/c-Met signaling in the brain. This promotes dendritic spine formation, synaptic connectivity, and neuronal repair. The mechanism is distinct from traditional nootropics.

Common Uses

Cognitive enhancementMemory improvementNeural repairAlzheimer's research

Dosage & Pharmacology

DOSAGE RANGE: 10-20 mg daily (oral or subcutaneous) — no established human protocol
HALF-LIFE: Unknown in humans (estimated 6-12 hours based on structure)
Dosage information is for research reference only. Not a recommendation.

Known Side Effects

  • Unknown (no human trials)
  • Theoretical cancer risk (HGF/c-Met pathway)
  • Headache (anecdotal)

Legal Status

US:Not FDA-approved, research chemical
UK:Not approved
EU:Not approved
AU:Not approved
View all Dihexa research on PubMed